// App-Quantinova.ai

179 : Asparaginase May Affect Mercaptopurine Tolerability in the Context of Multi-Agent Therapy for Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Chengcheng Liu

Principal Investigators

  • Deqing Pei

  • Cheng Cheng

  • Monika L. Metzger

  • Ching-Hon Pui

  • William E. Evans

  • Mary V. Relling

  • Jun J Yang

  • Kristine R Crews

  • John C Panetta

  • Xiangjun DeMeter

  • Sima Jeha

  • John Sandlund

  • Raul C. Ribeiro

  • Jeffrey E Rubnitz

Medical Centers

  • Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN

  • Department of Oncology and Global Medicine, International Outreach Program, St. Jude Children's Research Hospital, Memphis, TN

  • Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN

  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN

  • Pharmaceutical Sciences, St. Jude Children's Research Hospital, MEMPHIS, TN

  • Dep. Pharm. Sci., Hematologic Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN

  • St. Jude Children's Research Hospital, Memphis, TN

  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Thiopurine S-methyltransferase

Drug/Treatment

  • Allmercap

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Asparaginase

  • Elspar

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved